Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY3532226
Macupatide · 6 trials · 4 indications
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module
PD: AUC60-120min of plasma glucagon during the insulin-induced hypoglycemia
Change from Baseline in Total cDI
| Arm | Type | Description |
|---|---|---|
| Macupatide Dose 1 | EXPERIMENTAL | Participants will receive macupatide subcutaneously (SC) |
| Eloralintide Dose 1 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Macupatide Dose 1 + Eloralintide Dose 1 | EXPERIMENTAL | Participants will receive macupatide SC and eloralintide SC |
| Eloralintide Dose 2 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Macupatide Dose 1 + Eloralintide Dose 2 | EXPERIMENTAL | Participants will receive macupatide SC and eloralintide SC |
| Eloralintide Dose 3 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Macupatide Dose 2 + Eloralintide Dose 3 | EXPERIMENTAL | Participants will receive macupatide SC and eloralintide SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Macupatide (Macupatide + Eloralintide Placebo) | EXPERIMENTAL | Participants will be administered macupatide subcutaneously (SC) and eloralintide placebo SC |
| Eloralintide (Elorlintide + Macupatide Placebo) | EXPERIMENTAL | Participants will be administered eloralintide SC and macupatide placebo SC |
| Macupatide + Eloralintide | EXPERIMENTAL | Participants will be administered eloralintide SC and macupatide SC |
| Placebo (Macupatide Placebo + Elorlintide Placebo) | PLACEBO_COMPARATOR | Participants will be administered eloralintide placebo SC and macupatide placebo SC |
| Macupatide ＋ placebo | EXPERIMENTAL | Macupatide and placebo administered subcutaneously (SC) |
| Eloralintide + placebo | EXPERIMENTAL | Eloralintide and placebo administered SC |
| Macupatide Dose A + Eloralintide | EXPERIMENTAL | Macupatide and Eloralintide administered SC |
| Macupatide Dose B + Eloralintide | EXPERIMENTAL | Macupatide and Eloralintide administered SC |
| LY3532226 (Part A) | EXPERIMENTAL | LY3532226 administered subcutaneously (SC) |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 (Part B) | EXPERIMENTAL | LY3532226 administered SC |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 (Part C) | EXPERIMENTAL | LY3532226 administered SC |
| Placebo (Part C) | PLACEBO_COMPARATOR | Placebo administered SC |
| LY3532226 | EXPERIMENTAL | - |
| LY3532226 + Dulaglutide (Part A) | EXPERIMENTAL | LY3532226 administered subcutaneously (SC) followed by dulaglutide administered SC. |
| Placebo + Dulaglutide (Part A) | PLACEBO_COMPARATOR | Placebo administered SC followed by dulaglutide administered SC. |
| Dulaglutide + Placebo (Part B) | ACTIVE_COMPARATOR | Dulaglutide administered SC in combination with placebo given SC. |
| LY3532226 + Dulaglutide (Part B) | EXPERIMENTAL | LY3532226 administered SC in combination with Dulaglutide given SC. |
| LY3532226 + Placebo (Part B) | EXPERIMENTAL | LY3532226 administered SC in combination with placebo given SC. |
| Name | Type | Description |
|---|---|---|
| Macupatide | DRUG | Administered SC |
| Eloralintide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| Macupatide Placebo | DRUG | Administered SC |
| Eloralintide Placebo | DRUG | Administered SC |
| LY3532226 | DRUG | Administered SC |
| Dulaglutide | DRUG | Administered SC. |
Inclusion Criteria: * See Master Protocol CWMM (NCT06143956) for inclusion criteria Exclusion Criteria: In addition to exclusion criteria in Master Protocol CWMM (NCT06143956): * Have type 1 diabetes or type 2 diabetes * Have an ongoing history of bradyarrhythmia and/or sinus bradycardia * Have ...
Top 20 of 35 competitors
Macupatide is an investigational drug being studied for weight management in adults with obesity or overweight. It is also being tested in people with obesity or overweight who have type 2 diabetes. It has not been approved for any use and remains in clinical development.
Macupatide is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is running the clinical program, including studies of Macupatide alone and in combination with eloralintide.
Macupatide is in Phase 2 clinical development for obesity and overweight. One Phase 2 trial is currently recruiting, another Phase 2 trial is active but not recruiting, and a Phase 1 study in Japan has not yet started recruiting. It is not FDA approved.
Macupatide is being studied in NCT07589608, a recruiting Phase 2 trial of Macupatide and eloralintide alone or in combination in adults with obesity or overweight, and NCT07215559, an active Phase 2 trial in adults with obesity or overweight and type 2 diabetes. A Phase 1 trial, NCT07765511, is planned in Japan.
Yes, Macupatide is also known as LY3532226. Trial records list the drug under both names, so searches for either term refer to the same Eli Lilly investigational compound being studied for obesity and overweight.
The Macupatide trials are randomized, double-blind, and placebo-controlled, with about 400 participants enrolled in the Phase 2 study of Macupatide and eloralintide. Participants are adults aged 18 and older with obesity or overweight, and the studies are running in the United States and several other countries.